|
Dr Edward Keystone MD, FRCP, Professor of Medicine, University of Toronto, Director of the Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Mount Sinai Hospital, Canada discussing the effect of rituximab on radiographic progression in RTA patients and the capability of rituximab to reduce structural damage in RA patients.
|
|
Dr Axel Finckh, Rheumatology Division, University of Geneva, Switzerland comment on the need to monitor patients undergoing rituximab treatment to identify the optimum time to re-treat thus avoiding a deterioration of their condition to a pre-rituximab level.
|
|
Professor Tak, Professor of Medicine, Director, Division of Clinical Immunology and Rheumatology, EULAR & FOCIS Center of Excellence, Academic Medical Center, University of Amsterdam, The Netherlands commenting on :
- the need for an alternative RA treatment for patients who had deteriorated on other therapies
- the continued use of anti-TNF agents in RA patients
- the positive response achieved with rituximab in patients who had previously failed on other agents
|
